Please login to the form below

Not currently logged in
Email:
Password:

Industry veteran Louis Nisbet joins Sygnature board

Brings experience from Roche, Glaxo and SmithKline

Sygnature Louis NisbetSygnature Discovery has appointed Dr Louis Nisbet to its board as a non-executive director.

The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

Following this period, he became an entrepreneur, helping to found companies such as Xenova, Brax and InTouch with Health.

Dr Nisbet's current roles include serving as venture partner with Kurma Life Sciences Partners and chairman of the science park BioCity in Nottingham, UK.

Sygnature's CEO Dr Simon Hirst commented that Dr Nisbet joins the board at a time of growth for the company, which includes the recent addition of in vitro bioscience to its capabilities and enhancing its computational chemistry and informatics capabilities.

“Louis will provide us with advice and guidance as we continue our expansion and evolution as a business,” said Dr Hirst.

1st October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics